This page shows the latest IFM Tre news and features for those working in and with pharma, biotech and healthcare.
IFM Tre isn’t the only company working on inflammasomes, or indeed NLRP3. ... IFM Tre has only been in existence a few months, coalescing from assets that were left over when Bristol-Myers Squibb acquired IFM Therapeutics for $2.3bn in 2017.
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...